Assuming study is required, the following results were found.

  • Coronavirus Outbreak: Daily Updates

    As states have reopened, COVID-19 hotspots have appeared in multiple states including Arizona, Texas, and Florida. A new study out June 18 finds that using plasma from people who have recovered from COVID-19 is safe for people currently battling the...

    https://mschristian.org/index.php/articles/2-uncategorised/10909-coronavirus-outbreak-daily-updates
  • Coronavirus Outbreak: Daily Updates

    As states have reopened, COVID-19 hotspots have appeared in multiple states including Arizona, Texas, and Florida. A new study out June 18 finds that using plasma from people who have recovered from COVID-19 is safe for people currently battling the...

    https://mschristian.org/index.php/component/easyblog/coronavirus-outbreak-daily-updates?Itemid=101
  • Trials and Tribulations: Neurology Research During COVID-19 - Medscape

    safety considerations; and re-enlisting statisticians to keep their findings as significant as possible are just some of study survival strategies underway. Alzheimer's Disease Research on Hold The pandemic is having a significant impact on Alzheimer's...

    https://mschristian.org/index.php/component/easyblog/trials-and-tribulations-neurology-research-during-covid-19-medscape?Itemid=341
  • Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress - BioSpace

    a six-month assessment of patients with progressive multiple sclerosis (MS) enrolled in cohort 3 of an ATA188 Phase 1a study, Atara selected this cohort 3 dose to initiate the randomized, double-blind, placebo-controlled Phase 1b part of this study. “We...

    https://mschristian.org/index.php/component/easyblog/atara-biotherapeutics-announces-third-quarter-2019-financial-results-and-recent-clinical-operational-and-strategic-progress-biospace?Itemid=341
  • Trials and Tribulations: Neurology Research During COVID-19 - Medscape

    safety considerations; and re-enlisting statisticians to keep their findings as significant as possible are just some of study survival strategies underway. Alzheimer's Disease Research on Hold The pandemic is having a significant impact on Alzheimer's...

    https://mschristian.org/index.php/articles/2-uncategorised/10686-trials-and-tribulations-neurology-research-during-covid-19-medscape
  • U.K. to roll out the largest genetic study on chronic fatigue syndrome

    accepted definition, cause, diagnosis, and even treatment. Now, the United Kingdom is launching the first-ever genetic study on chronic fatigue syndrome, which affects 20 million people worldwide. In the U.K., it is believed that CFS affects about...

    https://mschristian.org/index.php/articles/2-uncategorised/10897-u-k-to-roll-out-the-largest-genetic-study-on-chronic-fatigue-syndrome
  • Fooling nerve cells into acting normal

    an fatal injury. What exactly signals neurons to keep acting and operating normally has not been known until now. In a new study, scientists at the University of Missouri have discovered that a neuron's own electrical signal, or voltage, can indicate...

    https://mschristian.org/index.php/component/easyblog/fooling-nerve-cells-into-acting-normal?Itemid=341
  • DOUBT Study Clarifies Role of MRI for TIA or Stroke

    earn free cme credit Earn CME credit by reading this article and completing the posttest. Sign Up Study Authors: Shelagh B. Coutts, Francois Moreau, et al.; Margy E. McCullough-Hicks, Gregory W. Albers Target Audience and Goal Statement: Neurologists,...

    https://mschristian.org/index.php/articles/2-uncategorised/8834-doubt-study-clarifies-role-of-mri-for-tia-or-stroke
  • U.K. to roll out the largest genetic study on chronic fatigue syndrome

    accepted definition, cause, diagnosis, and even treatment. Now, the United Kingdom is launching the first-ever genetic study on chronic fatigue syndrome, which affects 20 million people worldwide. In the U.K., it is believed that CFS affects about...

    https://mschristian.org/index.php/component/easyblog/u-k-to-roll-out-the-largest-genetic-study-on-chronic-fatigue-syndrome?Itemid=101
  • International MS Genetics Consortium Confirms 233 MS-Related Gene Variations in Largest Study to Date

    September 26, 2019 SUMMARY:The International MS Genetics Consortium (IMSGC) has published the largest MS genetics study to date, analyzing data from 47,429 people with MS and 68,374 individuals without MS.They confirmed 233 variations in the human...

    https://mschristian.org/index.php/component/easyblog/international-ms-genetics-consortium-confirms-233-ms-related-gene-variations-in-largest-study-to-date?Itemid=341
  • Do minerals play a role in development of multiple sclerosis?

    it. But little was known about whether zinc, iron and other minerals play a role in the development of the disease. A new study shows no link between dietary intake of several minerals and whether people later develop MS. The study is published in the...

    https://mschristian.org/index.php/component/easyblog/do-minerals-play-a-role-in-development-of-multiple-sclerosis?Itemid=341
  • Novartis receives positive CHMP opinion for Mayzent® (siponimod) for the treatment of adult patients with active secondary progressive multiple sclerosis (SPMS) | Small Molecules | News Channels - PipelineReview.com

    multiple sclerosis (SPMS) in Europe[1])CHMP opinion is based on the Phase III EXPAND trial, the largest randomized clinical study in a broad SPMS patient population (EDSS score 3.0 to 6.5 at baseline), showing Mayzent significantly reduced the risk of...

    https://mschristian.org/index.php/component/easyblog/novartis-receives-positive-chmp-opinion-for-mayzent-siponimod-for-the-treatment-of-adult-patients-with-active-secondary-progressive-multiple-sclerosis-spms-small-molecules-news-channels-pipelinereview-com?Itemid=341
  • Atara Biotherapeutics Announces Third Quarter 2019 Financial Results and Recent Clinical, Operational and Strategic Progress - BioSpace

    a six-month assessment of patients with progressive multiple sclerosis (MS) enrolled in cohort 3 of an ATA188 Phase 1a study, Atara selected this cohort 3 dose to initiate the randomized, double-blind, placebo-controlled Phase 1b part of this study. “We...

    https://mschristian.org/index.php/articles/2-uncategorised/9192-atara-biotherapeutics-announces-third-quarter-2019-financial-results-and-recent-clinical-operational-and-strategic-progress-biospace
  • Genomic map implicates broad immune cell involvement in multiple sclerosis

    The International Multiple Sclerosis Genetic Consortium (IMSGC) reports the results of its latest study, "Multiple sclerosis genomic map implicates peripheral immune cells and microglia in susceptibility," in the journal Science today: the highly...

    https://mschristian.org/index.php/articles/2-uncategorised/8755-genomic-map-implicates-broad-immune-cell-involvement-in-multiple-sclerosis
  • International MS Genetics Consortium Confirms 233 MS-Related Gene Variations in Largest Study to Date

    September 26, 2019 SUMMARY:The International MS Genetics Consortium (IMSGC) has published the largest MS genetics study to date, analyzing data from 47,429 people with MS and 68,374 individuals without MS.They confirmed 233 variations in the human...

    https://mschristian.org/index.php/articles/2-uncategorised/9087-international-ms-genetics-consortium-confirms-233-ms-related-gene-variations-in-largest-study-to-date
  • AJMC® in the Press, September 13, 2019 - AJMC.com Managed Markets Network

    Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press. A study published in this month’s issue ofThe American Journal of Managed Care®(AJMC®) evaluated the patterns of clinical service for long-term nursing...

    https://mschristian.org/index.php/component/easyblog/ajmc-in-the-press-september-13-2019-ajmc-com-managed-markets-network?Itemid=341
  • Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy | Antibodies | News Channels - PipelineReview.com

    Details Hits: 97 The primary endpoint of the Phase 2 PASSPORT study was not met, and further development of gosuranemab in progressive supranuclear palsy (PSP) will not be pursued CAMBRIDGE, MA, USA I December 13, 2019 IToday, Biogen Inc. (Nasdaq:...

    https://mschristian.org/index.php/articles/2-uncategorised/9544-biogen-reports-top-line-results-from-phase-2-study-in-progressive-supranuclear-palsy-antibodies-news-channels-pipelinereview-com
  • Study reveals neural mechanisms underlying state mental fatigue in multiple sclerosis

    Reviewed by Emily Henderson, B.Sc.Jul 28 2020 Researchers at Kessler Foundation conducted a pilot study comparing the effects of mental fatigue on brain activation patterns in people with and without multiple sclerosis (MS). Their findings indicate...

    https://mschristian.org/index.php/articles/2-uncategorised/10977-study-reveals-neural-mechanisms-underlying-state-mental-fatigue-in-multiple-sclerosis
  • Missing one night of sleep may increase Alzheimer's biomarker, study finds

    Reviewed by Kate Anderton, B.Sc. (Editor)Jan 8 2020 A preliminary study has found that when young, healthy men were deprived of just one night of sleep, they had higher levels of tau, a biomarker for Alzheimer's disease, in their blood than when they...

    https://mschristian.org/index.php/articles/2-uncategorised/9710-missing-one-night-of-sleep-may-increase-alzheimer-s-biomarker-study-finds
  • Biogen Reports Top-Line Results from Phase 2 Study in Progressive Supranuclear Palsy | Antibodies | News Channels - PipelineReview.com

    DetailsHits: 97 The primary endpoint of the Phase 2 PASSPORT study was not met, and further development of gosuranemab in progressive supranuclear palsy (PSP) will not be pursued CAMBRIDGE, MA, USA I December 13, 2019 IToday, Biogen Inc. (Nasdaq: BIIB)...

    https://mschristian.org/index.php/component/easyblog/biogen-reports-top-line-results-from-phase-2-study-in-progressive-supranuclear-palsy-antibodies-news-channels-pipelinereview-com?Itemid=341

Results 1 - 20 of 588